Post-covid syndrome, possibilities for therapy of asthenic disorders with Selank
- Authors: Pogodina М.G.1, Nikiforova Е.1
-
Affiliations:
- Kuban State Medical University, Ministry of Health of Russia
- Issue: Vol 35, No 5 (2024)
- Pages: 65-72
- Section: From Practice
- URL: https://journals.eco-vector.com/0236-3054/article/view/633315
- DOI: https://doi.org/10.29296/25877305-2024-05-12
- ID: 633315
Cite item
Abstract
Post-COVID syndrome develops after a COVID-19 infection, and is also observed in cases of mild or asymptomatic course of the disease. The most common symptoms of bridge syndrome are asthenia and decreased performance, with further development of cognitive deficit. Taking into account the leading role of immune disorders in the pathogenesis of COVID-19, the use of immunotropic drugs that have both direct activity in relation to immune interactions and those that work indirectly through the reduction of post-stress reactions that can maintain immune dysfunction seems promising. In this regard, Selank is of interest, a peptide created on the basis of the immune regulator tafcin, which has proven itself well in the treatment of a wide range of neurotic and neurosis–like disorders.
Objective. To study the efficacy of the drug Selank in patients with complaints of asthenia, decreased performance and emotional disorders that developed after COVID-19 infection.
Material and methods. The study included 64 patients divided into 2 groups: Group 1 (n=32) – patients received neuroprotective complex (cholitilin, mexidol, milgamma) and the drug Selank; Group 2 (n=32) – patients received neuroprotective complex (cholitilin, mexidol, milgamma) without the drug Selank.
Results. The drug Selank (nasal drops, 1.5 mg) when used at a dose of 2-3 drops 4 times a day for 30 days showed a good effect in patients with asthenia and impaired mental performance. In parallel, relief of anxiety and depressive symptoms was observed. Based on the data obtained, it can be argued that Selank demonstrates a good effect when used in patients with asthenia, which developed as a result of a previous COVID-19 viral infection, with concomitant depressive and anxiety symptoms.
Full Text

About the authors
М. G. Pogodina
Kuban State Medical University, Ministry of Health of Russia
Author for correspondence.
Email: m.g.pogodina@mail.ru
Russian Federation, Krasnodar
Е. Nikiforova
Kuban State Medical University, Ministry of Health of Russia
Email: m.g.pogodina@mail.ru
Russian Federation, Krasnodar
References
- Андреева Л.А., Мезенцева М.В., Наровлянский А.Н. и др. Перспективы создания новых пептидных лекарственных препаратов, обладающих противоинфекционной и иммуномодулирующей активностью. Инфекция и иммунитет. 2011; 1 (2): 171–6 [Andreeva L.A., Mezentseva M.V., Narovlianskiy A.N. et al. The perspectives of development of new peptide preparations for clinical use which have anti-infection and immune-modulating activity. Infekc immun. 2011; 1 (2): 171–6 (in Russ.)].
- Белоглазов В.А., Вербенко В.А., Лугачев Б.И. Применение интраназального препарата Селанк 0,15% с целью психофармакологической коррекции в комплексной терапии пациентов с бронхиальной астмой. Поликлиника. 2019; 3: 34–8 [Beloglazov V.A., Verbenko V.A., Lugachov B.I. The use of intranasal drug Selank 0,15% for the purpose of psychopharmacological correction in the treatment of patients with bronchial asthma. Poliklinika. 2019; 3: 34–8 (in Russ.)].
- Вербенко В.А., Шакина Т.А. Новые возможности потенцирования действия селективных ингибиторов обратного захвата серотонина регуляторным пептидом Селанк при терапии тревожно-депрессивных расстройств. Врач. 2019; 30 (10): 76–81 [Verbenko V., Shakina T. New possibilities for potentiating the effects of antidepressants of the group of selective serotonin reuptake inhibitors by the regulatory peptide Selank in the treatment of anxiety and depressive disorders. Vrach. 2019; 30 (10): 76–81 (in Russ.)]. doi: 10.29296/25877305-2019-10-16
- Особенности анксиолитического и стрессопротективного действия пептидного препарата Селанк® при терапии расстройств адаптации и посттравматического стрессового расстройства. Медицинский алфавит. 2017; 3 (32): 21–6 [Verbenko V.A., Shakina T.A. Effectiveness of new synthesized analogue of endogenous peptide taftcin – Selank in therapy of adjustment and posttraumatic stress disorders. Medical alphabet. 2017; 3 (32): 21–6 (in Russ.)].
- Вербенко В.А., Федоров В.Н. Оптимизация терапии тревожных расстройств. Таврический журнал психиатрии. 2016; 20 (3): 5–14 [Verbenko V.A., Fedorov V.N. Optimization of therapy for anxiety disorders. Tauride Journal of Psychiatry. 2016; 20 (3): 5–14 (in Russ.)].
- Высоков И.Е. Математические методы в психологии: учебник и практикум для вузов. 3-е изд., перераб. и доп. М.: Издательство Юрайт, 2024 [Vysokov I.E. Mathematical methods in psychology: textbook and workshop for universities. 3rd ed., revised. and add. M.: Yurayt Publishing House, 2024 (in Russ.)].
- Захаров В.В., Громова Д.О., Эдильгиреева Л.А. и др. Когнитивные и астенические расстройства после COVID-19. РМЖ. 2022; 4: 15–9 [Zakharov V.V., Gromova D.O., Edilgireeva L.A. et al. Cognitive and asthenic disorders after COVID-19. RMJ. 2022; 4: 15–9 (in Russ.)].
- Зозуля Ф.Ф., Незнамов Г.Г., Сюняков Т.С. и др. Эффективность и возможные механизмы действия нового анксиолитика селанка при терапии генерализованного тревожного расстройства и неврастении. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008; 108 (4): 38–48 [Zozulia A.A., Neznamov G.G., Siuniakov T.S. et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2008; 108 (4): 38–48 (in Russ.)].
- Зуева И.Б., Ким Ю.В., Суслова М.Ю. Постинфекционная астения у пациентов, перенесших COVID-19 на амбулаторном этапе. Международный журнал сердца и сосудистых заболеваний. 2022; 10 (33.1): 18–20 [Zueva I.B., Kim Yu.V., Suslova M.Yu. Post-viral asthenia in patients with COVID-19 who received outpatient care. International Heart and Vascular Disease Journal. 2022; 10 (33.1): 24–30 (in Russ.)]. doi: 10.24412/2311-1623-2022-33.1-24-30
- Кобзарь А.И. Прикладная математическая статистика. М.: Физматлит, 2006; с. 626–8 [Kobzar A.I. Applied mathematical statistics. M.: Fizmatlit, 2006; рр. 626–8 (in Russ.)].
- Компьютерная психологическая диагностика. Электронный ресурс [Computerized psychological diagnostics. Electronic resource (in Russ.)]. URL: https://cpd-program.ru/methods.html
- Королева С.В., Мясоедов Н.Ф. Физиологические эффекты Селанка и его фрагментов. Известия РАН. Серия биологическая. 2019; 4: 429–38 [Koroleva S.V., Mjasoedov N.F. Physiological Effects of the Selank and Its Fragments. Proceedings of the Russian Academy of Sciences. Biological Series. 2019; 4: 429–38 (in Russ.)]. doi: 10.1134/S0002332919040076
- Косенко В.Г., Никифорова Е.Ю., Погодина М.Г. и др. Особенности психологических защит в период пандемии COVID-19. Психическое здоровье. 2022; 17 (3): 19–26 [Kosenko V.G., Nikiforova E.YU., Pogodina M.G. et al. Features of psychological defenses during the COVID-19 pandemic. Mental Health. 2022; 17 (3): 19–26 (in Russ.)]. doi: 10.25557/2074-014X.2022.03.19-26
- Медведев В.Э. Терещенко О.Н., Кост Н.В. и др. Оптимизация терапии тревожных расстройств пептидным препаратом Селанк. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015; 115 (6): 33–40 [Medvedev V.E., Tereshchenko O.N., Kost N.V. et al. Optimization of the treatment of anxiety disorders with selank. S.S. Korsakov Journal of Neurology and Psychiatry. 2015; 115 (6): 33–40 (in Russ.)]. doi: 10.17116/jnevro20151156133-40
- Опросник выраженности психопатологической симптоматики. Электронный ресурс [Questionnaire of the expression of psychopathologic symptomatology. Electronic resource (in Russ.)]. URL: https://studfile.net/preview/3535528/page:5/
- Редько А.Н., Косенко В.Г., Косенко Н.А. и др. Социодемографические и клинические особенности у лиц с психическими расстройствами, обращающихся в негосударственные медицинские учреждения в период пандемии COVID-19 и первого года ее течения (2019-2020). Социальная и клиническая психиатрия. 2022; 32 (1): 74–81 [Redko A.N., Kosenko V.G., Kosenko N.A. et al. Sociodemographic and clinical features of persons with mental disorders who apply to non-governmental medical institutions in the period before the COVID-19 pandemic and the first year of its course (2019-2020). Social and clinical psychiatry. 2022; 32 (1): 74–81 (in Russ.)].
- Скребицкий В.Г., Шаронова И.Н. Технологии изучения механизмов действия препаратов для коррекции когнитивных расстройств. Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений. 2018; 2: 10–20 [Skrebitsky V.G., Sharonova I.N. Technologies of studying the mechanisms of action of drugs for the correction of cognitive disorders. Bulletin of the National Society for the Study of Parkinson's Disease and Movement Disorders. 2018; 2: 10-20 (in Russ.)]. doi: 10.24411/2071-5315-2018-12025
- Солдаткин В.А., Ковалев А.И., Крючкова М.Н. и др. Клиническая психометрика: учебное пособие. Ростов-на-Дону: Изд-во РостГМУ, 2020; с. 80–7 [Soldatkin V.A., Kovalev A.I., Kryuchkova M.N. et al. Clinical psychometrics: textbook. Rostov-on-Don: Rostov State Medical University Publishing House, 2020; рр. 80–7 (in Russ.)]..
- Соллертинская Т.Н., Шорохов М.В., Мясоедов Н.Ф. и др. Пептидные биорегуляторы семакс и селанк в компенсации нарушенных когнитивных функций и межполушарной асимметрии у приматов. Асимметрия. 2014; 8 (4): 53–65 [Sollertinskaja T.N., Shorokhov M.V., Myasoedov N.F. et al. The peptide bioregulators semax and selank in cognitive function disturbance compensation and brain interhemispheric asymmetry in primates. Journal of asymmetry. 2014; 8 (4): 53–65 (in Russ.)].
- Субъективная шкала оценки астении. Электронный ресурс [Subjective assessment scale for asthenia. Electronic resource (in Russ.)]. URL: https://ra-kurs-sochi.ru/ekspress-test#gallery-2
- Танашян М.М., Раскуражев А.А., Кузнецова П.И. и др. Перспективы и возможности терапии пациентов с астеническим синдромом после перенесенной новой коронавирусной инфекции COVID-19. Терапевтический архив. 2022; 94 (11): 1285–93 [Tanashyan M.M., Raskurazhev A.A., Kuznetsova P.I. et al. Prospects and possibilities for the treatment of patients with long COVID-19 syndrome. Terapevticheskii Arkhiv. 2022; 94 (11): 1285–93 (in Russ.)]. doi: 10.26442/00403660.2022.11.201981
- Хасанова Д.Р., Житкова Ю.В., Васкаева Г.Р. Постковидный синдром: обзор знаний о патогенезе, нейропсихиатрических проявлениях и перспективах лечения. Неврология, нейропсихиатрия, психосоматика. 2021; 13 (3): 93–8 [Khasanova D.R., Zhitkova Yu.V., Vaskaeva G.R. Post-covid syndrome: a review of pathophysiology, neuropsychiatric manifestations and treatment perspectives. Neurology, Neuropsychiatry, Psychosomatics. 2021; 13 (3): 93–8 (in Russ.)]. doi: 10.14412/2074-2711-2021-3-93-98
- Тафтсин, Селанк и аналоги. Иммунитет, антистресс, либидо [Tuftsin, Selank and analogs. Immunity, anti-stress, libido (in Russ.)]. URL: https://russianpeptide.com/taftsin-selank-i-analogi-immunitet-antistress-libido/
- Ясенявская А.Л., Самотруева М.А., Башкина О.А. и др. Нейропептидная регуляция иммунитета. Иммунология. 2018; 39 (5-6): 326–36 [Yasenyavskaya A.L., Samotrueva M.A., Bashkina O.A. et al. Neuropeptide regulation of immunity. Immunologiya. 2018; 39 (5-6): 326–36 (in Russ.)]. doi: 10.18821/0206-4952-2018-39-5-6-326-336
- Alemanno F., Houdayer E., Parma A. et al. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID rehabilitation unit experience. PLoS One. 2021; 16: e0246590. doi: 10.1371/journal.pone.0246590
- Ali Awan H., Najmuddin Diwan M., Aamir A. et al. SARS-CoV-2 and the Brain: What Do We Know about the Causality of «Cognitive COVID». J Clin Med. 2021; 10 (15): 3441. doi: 10.3390/jcm10153441
- Almeria M., Cejudo J.C., Sotoca J. et al. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health. 2020; 9: 100163. doi: 10.1016/j.bbih.2020.100163
- Amenta E.M., Spallone A., Rodriguez Barradas M.C. et al. Post-acute COVID-19: An overview and approach to classification. Open Forum Infect Dis. 2020; 7 (12): ofaa509. doi: 10.1093/ofid/ofaa509
- Baig A., Khaleeq A., Ali U. et al. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution. Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosc. 2020; 11 (7): 995–8. doi: 10.1021/acschemneuro.0c00122
- Berlit P., Frölich L., Förstl H. The «Fourth Wave»? COVID-19 and consecutive cognitive impairment. Dtsch Med Wochenschr. 2021; 146 (10): 671–6. doi: 10.1055/a-1468-1529
- Bradburn S., Sarginson J., Murgatroyd C.A. Association of Peripheral Interleukin-6 with Global Cognitive Decline in Non-demented Adults: A Meta-Analysis of Prospective Studies. Front Aging Neurosci. 2018; 9: 438. doi: 10.3389/fnagi.2017.00438
- Chih-Sung Liang, Kuan-Pin Su, Chia-Lin Tsai et al. The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease. Alzheimers Res Ther. 2020; 12 (1): 86. doi: 10.1186/s13195-020-00652-z
- Davis H.E., Assaf G.S., McCorkell L. et al. Characterizing Long COVID in an International Cohort:7 Months of Symptoms and Their Impact. medRxiv preprint. doi: 10.1101/2020.12.24.20248802. URL: https://www.medrxiv.org/content/10.1101/2020.12.24.20248802v3
- Goеrtz Y.M.J., van Herck M., Delbressine J.M. et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the postCOVID-19 syndrome? ERJ Open Res. 2020; 6 (4): 00542-2020. doi: 10.1183/23120541.00542-2020
- Greenhalgh T., Knight M., A’Court M. et al. Management of post-acute COVID-19 in primary care. BMJ. 2020; 370: m3026. doi: 10.1136/bmj.m3026
- Hakamata Y., Suzuki Y,, Kobashikawa H. et al. Neurobiology of early life adversity: A systematic review of meta-analyses towards an integrative account of its neurobiological trajectories to mental disorders. Front Neuroendocrinol. 2022; 65: 100994. doi: 10.1016/j.yfrne.2022.100994
- Haijing Ma, Jiatong Xu, Ruonan Li et al. The Impact of Cognitive Behavioral Therapy on Peripheral Interleukin-6 Levels in Depression: A Systematic Review and Meta-Analysis. Front Psychiatry. 2022; 13: 844176. doi: 10.3389/fpsyt.2022.844176
- Halpin S.J., McIvor C., Whyatt E.G. et al. Post-discharge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021; 93: 1013–22. doi: 10.1002/jmv.26368
- Helms J., Kremer S., Merdji H. et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020; 382 (23): 2268–70. doi: 10.1056/NEJMc2008597
- Jaywant A., Vanderlind W.M., Alexopoulos G.S. et al. Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19. Neuropsychopharmacology. 2021; 10: 1–6. doi: 10.1038/s41386-021-00978-8
- Maltezou H.C., Pavli A., Tsakris A. Post-COVID Syndrome: An Insight on Its Pathogenesis. Vaccines (Basel). 2021; 9 (5): 497. doi: 10.3390/vaccines9050497
- Maltezou H.C., Raftopoulos V., Vorou R. et al. Association between upper respiratory tract viral load, comorbidities, disease severity, and outcome of patients with SARS-CoV-2 infection. J Infect Dis. 2021; 223 (7): 1132–8. doi: 10.1093/infdis/jiaa804
- Mazza M.G., Palladini M., De Lorenzo R. et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun Health. 2021; 94: 138–47. doi: 10.1016/j.bbi.2021.02.021
- Mendez R., Balanza-Martinez V., Luperdi S.C. et al. Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. J Intern Med. 2021; 290 (3): 621–31. doi: 10.1111/joim.13262
- Nalbandian A., Sehgal K., Gupta A. et al. Post-acute COVID-19 syndrome. Nat Med. 2021; 27 (4): 601–15. doi: 10.1038/s41591-021-01283-z
- Pavli A., Theodoridou M., Maltezou H.C. Post-COVID syndrome: Incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch Med Res. 2021; 52 (6): 575–81. doi: 10.1016/j.arcmed.2021.03.010
- Pilotto A., Cristillo V., Cotti Piccinelli S. et al. COVID-19 severity impacts on long-term neurological manifestation after hospitalisation. medRxiv preprint. doi: 10.1101/2020.12.27.20248903. URL: https://www.medrxiv.org/content/10.1101/2020.12.27.20248903v1.full.pdf
- Ritchie K., Chan D., Watermeyer T. The cognitive consequences of the COVID-19 epidemic: collateral damage? Brain Commun. 2020; 2 (2): fcaa069. doi: 10.1093/braincomms/fcaa069
- Rogers J.P., Chesney E., Oliver D. et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020; 7 (7): 611–27. doi: 10.1016/S2215-0366(20)30203-0
- Stefano G.B., Büttiker P., Weissenberger S. et al. Editorial: The Pathogenesis of Long-Term Neuropsychiatric COVID-19 and the Role of Microglia, Mitochondria, and Persistent Neuroinflammation: A Hypothesis. Med Sci Monit. 2021; 27: e933015. doi: 10.12659/MSM.933015
- Shih-Jen Tsai. Role of interleukin 8 in depression and other psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2021; 106: 110173. doi: 10.1016/j.pnpbp.2020.110173
- Tayebati S.K., Amenta F., Tomassoni D. Cerebrovascular and blood-brain barrier morphology in spontaneously hypertensive rats: effect of treatment with choline alphoscerate. CNS Neurol Disord Drug Targets. 2015; 14 (3): 421–9. doi: 10.2174/1871527314666150225140855
- Traini E., Bramanti V., Amenta F. Choline alphoscerate (alpha-glyceryl-phosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. Curr Alzheimer Res. 2013; 10 (10): 1070–9. doi: 10.2174/15672050113106660173
- Wijeratne T., Crewther S. Post-COVID 19 Neurological Syndrome (PCNS); a novel syndrome with challenges for the global neurology community. J Neurol Sci. 2020; 419: 117179. doi: 10.1016/j.jns.2020.117179
- Yuan Zhang, Jingjing Wang, Yu Ye et al. Peripheral cytokine levels across psychiatric disorders: A systematic review and network meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2023; 125: 110740. doi: 10.1016/j.pnpbp.2023.110740
Supplementary files
